Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
  • C07F1/04—Sodium compounds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention is directed to novel crystalline forms of Fluvastatin sodium, processes for their preparation and pharmaceutical compositions comprising these crystalline forms.
• Fluvastatin sodium is known by its chemical name ( ⁇ )-7-(3-(4-fluorophenyl)-1-(1- methylethyl)-1 H-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt.
• Fluvastatin sodium is a racemic mixture of the 3R.5S- and 3S,5R-dihydroxy enantiomers and has the following formula:
• Fluvastatin sodium is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) and is used to lower the blood cholesterol level.
• HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A
• Fluvastatin as well its sodium salt are disclosed in US-A-4,739,073.
• Fluvastatin sodium is obtained by lyophilization.
• WO-A-97/49681 and its US equivalent US-A-6, 124,340 describe that lyophilization of Fluvastatin sodium yields a mixture of a crystalline form, designated as Form A, and amorphous material, and disclose a new crystalline form, designated as Form B.
• the estimated amount of form A obtained by lyophilization as described in these patents is about 50%.
• the crystalline Form B is obtained either by transformation of material containing Form A in a slurry of a mixture of an organic solvent and water, or by crystallization from an organic solvent and water mixture.
• Form B is less hygroscopic than Form A or the amorphous form of Fluvastatin sodium which improves handling and storage of the compound.
• Fluvastatin sodium can be prepared as novel crystalline hydrates which have improved stability and are obtained from aqueous solutions without the risk of residual organic solvent.
• These novel crystalline hydrates herein designated as Form C, D, E and F, are less susceptible towards air humidity, and show high stability and are easier to handle at normal environmental humidity levels.
• the novel crystalline forms of Fluvastatin sodium are novel hydrates with water contents ranging from 3 to 32%.
• the present invention provides the following novel crystalline forms of Fluvastatin sodium:
• a crystalline polymorph of ( ⁇ )-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indoI-2-yl)-3,5- dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (A): 23.8 (vs), 11.8 (w), 7.8 (vs), 7.6 (vw), 7.4 (vw), 6.4 (vw), 6.1 (vw), 5.90 (w), 5.00 (vw), 4.88 (w), 4.73 (m), 4.56 (w), 4.40 (vw), 4.12 (vw), 4.03 (vw), 3.96 (vw), 3.50 (vw), 3.36 (vw), 2.93 (vw), herein designated as Form C.
• a crystalline polymorph of ( ⁇ )-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5- dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (A): 24.6 (vs), 12.5 (w), 8.3 (vs), 7.4 (vw), 6.2 (m), 4.97 (w), 4.85 (vw), 4.52 (vw), 4.40 (vw), 4.14 (vw), 3.96 (vw), 3.41 (vw), 3.10 (vw), herein designated as Form D.
• a characteristic X-ray powder diffraction pattern for Form D is depicted in Figure 3.
• a crystalline polymorph of ( ⁇ )-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5- dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (A): 27.6 (m), 13.9 (vw), 9.2 (m), 8.5 (vw), 8.1 (vw), 7.4 (vw), 6.9 (s), 6.1 (vw), 4.98 (m), 4.77 (m), 4.63 (m), 4.15 (w), 4.03 (w), 3.97 (vw), 3.52 (vw), 3.33 (vw), 3.08 (vw), 2.99 (vw), herein designated as Form E.
• a characteristic X-ray powder diffraction pattern for Form E is depicted in Figure 4.
• a crystalline polymorph of ( ⁇ )-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5- dihydroxy-6-heptenoic acid monosodium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (A): 29.6 (w), 14.8 (vw), 9.9 (w), 8.6 (vw), 8.3 (vw), 7.4 (s), 6.6 (vw), 6.2 (vw), 5.93 (w), 5.03 (m), 4.94 (m), 4.35 (vw), 4.23 (w), 3.98 (vw), 3.54 (vw), 2.98 (vw), herein designated as Form F.
• a characteristic X-ray powder diffraction pattern for Form F is depicted in Figure 5.
• the present invention is directed to processes for the preparation of Form C, D, E, F and highly crystalline Form A.
• Forms C, D, E and F can be prepared according to a process, wherein Fluvastatin sodium is exposed to an atmosphere having a defined relative humidity.
• Form C of Fluvastatin sodium can generally be prepared from either the crystalline Forms A, D, E, F or amorphous Fluvastatin sodium, or mixtures thereof, for example by equilibration under relative humidity conditions from about 15 to 25% (for example for 6 to 24 hours). As a rule the estimated water content can range from 3-6%.
• Form D of Fluvastatin sodium can generally be prepared from either the crystalline Forms A, C, E, F or amorphous Fluvastatin sodium, or mixtures thereof, for example by equilibration under relative humidity conditions from about 30 to 50% (for example for 6 to 24 hours). As a rule the estimated water content can range from 6-12%.
• Form E of Fluvastatin sodium can generally be prepared from either the crystalline Form A, C, D, F or amorphous Fluvastatin sodium, or mixtures thereof, for example by equilibration under relative humidity conditions from about 55 to 75% (for example for several days). As a rule the estimated water content can range from 15-22%.
• Form F of Fluvastatin sodium can generally be prepared from either the crystalline Form A, C, D, E or amorphous Fluvastatin sodium, or mixtures thereof, for example by equilibration under relative humidity conditions from about 80 to 90% (for example for several days). As a rule the estimated water content can range from 24-32%.
• Highly crystalline Fluvastatin sodium Form A can generally be prepared by equilibration of an aqueous suspension or solution of Fluvastatin sodium for several hours at temperatures from about 0 to 10°C and subsequent drying by lyophilization. The process can be accelerated by additional seeding with crystals of Form A during the equilibration period.
• a characteristic X-ray powder diffraction pattern for highly crystalline Form A is depicted in Figure 1. The crystallinity of this material is estimated by the powder diffraction spectrum to be more than 90%. The estimated water content is below 2%.
• a preferred process for the preparation of highly crystalline Fluvastatin sodium Form A comprises treating an aqueous solution of ( ⁇ )-7-(3-(4-fluorophenyl)-1-(1-methyIethyl)-1H- indoI-2-yl)-3,5-dihydroxy-6-heptenoic acid monosodium salt in order to effect at least minimal precipitation of the compound, followed by freeze drying.
• the aqueous solution is cooled and subsequently the suspension is freeze dried.
• the aqueous solution is prepared at a temperature of 20 to 80°C, especially 30 to 80°C, and is cooled to a temperature of 0 to 15°C in order to effect precipitation of the compound.
• Advantagously seeding crystals of Form A can be added.
• crystalline Fluvastatin sodium Form D prepared under a relative humidity of 35% exhibits characteristic X-ray powder diffraction peaks in d-values (A) at 24.6 (vs), 12.5 (w), 8.3 (vs) and 6.2 (m), whereas a sample prepared under a relative humidity of 50% exhibits characteristic X-ray powder diffraction peaks in d-values (A) at 26.2 (vs), 13.2 (w), 8.9 (vs) and 6.7 (m), see Figure 6.
• compositions comprising an effective amount of crystalline polymorphic Form C, D, E or F, and a pharmaceutically acceptable carrier.
• Another subject of the present invention are pharmaceutical compositions comprising an effective amount of highly crystalline polymorphic Form A, and a pharmaceutically acceptable carrier.
• the polymorphic forms may be used as single components or mixtures.
• compositions of Fluvastatin sodium it is preferred that these contain 25-100% by weight, especially 50-100% by weight, of at least one of the novel forms, based on the total amount of Fluvastatin sodium.
• an amount of the novel polymorphic forms of Fluvastatin sodium is 75-100% by weight, especially 90-100% by weight. Highly preferred is an amount of 95-100% by weight.
• Example 1 Preparation of highly crystalline polymorphic Form A
• Fluvastatin sodium obtained by lyophilization, was stored over a saturated solution of MgCI 2 6H 2 O at ambient temperature, i.e. under an humidity of approximately 33% for about 12 hours.
• the obtained sample is crystalline and corresponds to Fluvastatin sodium Form D, see Figure 3.
• Figure 1 is a characteristic X-ray powder diffraction pattern for highly crytalline Form A.
• Figure 2 is a characteristic X-ray powder diffraction pattern for Form C.
• Figure 3 is a characteristic X-ray powder diffraction pattern for Form D.
• Figure 4 is a characteristic X-ray powder diffraction pattern for Form E.
• Figure 5 is a characteristic X-ray powder diffraction pattern for Form F.
• Figure 6 shows the small deviations between characteristic X-ray powder diffraction patterns for Form D measured at 35 and 50% relative air humidity.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Indole Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (2)

Family

ID=8184071

Family Applications (1)

Country Status (16)

Cited By (7)

Families Citing this family (17)

Family Cites Families (7)

• 2002
  • 2002-07-25 CA CA002454072A patent/CA2454072A1/en not_active Abandoned
  • 2002-07-25 KR KR1020047001615A patent/KR100975782B1/ko not_active Expired - Fee Related
  • 2002-07-25 EP EP02794517A patent/EP1429757B8/en not_active Expired - Lifetime
  • 2002-07-25 WO PCT/EP2002/008276 patent/WO2003013512A2/en not_active Ceased
  • 2002-07-25 ES ES02794517T patent/ES2304140T3/es not_active Expired - Lifetime
  • 2002-07-25 AT AT02794517T patent/ATE391502T1/de not_active IP Right Cessation
  • 2002-07-25 HU HU0401141A patent/HUP0401141A3/hu unknown
  • 2002-07-25 RU RU2004106528/04A patent/RU2334738C2/ru not_active IP Right Cessation
  • 2002-07-25 DE DE60226044T patent/DE60226044T2/de not_active Expired - Lifetime
  • 2002-07-25 CN CN028151321A patent/CN1536999B/zh not_active Expired - Fee Related
  • 2002-07-25 IL IL15986102A patent/IL159861A0/xx active IP Right Grant
  • 2002-07-25 PL PL02366905A patent/PL366905A1/xx not_active Application Discontinuation
  • 2002-07-25 JP JP2003518521A patent/JP4681808B2/ja not_active Expired - Fee Related
  • 2002-07-25 AU AU2002333271A patent/AU2002333271B2/en not_active Ceased
  • 2002-07-25 CN CN2011103995817A patent/CN102516150A/zh active Pending
  • 2002-07-30 US US10/208,687 patent/US6696479B2/en not_active Expired - Lifetime
  • 2002-08-01 AR ARP020102927A patent/AR036205A1/es unknown
• 2004
  • 2004-01-14 IL IL159861A patent/IL159861A/en not_active IP Right Cessation
• 2010
  • 2010-07-23 JP JP2010165635A patent/JP2010265308A/ja active Pending

Also Published As

Similar Documents

Legal Events